Imaging software developer Median Technologies has been selected to provide imaging software and services for three new clinical trials worth a total of 1.58 million euros.
Median will help manage medical images in a phase III study for non-small cell lung cancer and in a phase II study for bladder cancer. The other contract is with an Asian biotech company to manage imaging in a phase II study for breast cancer.
Together, the trials will involve more than 280 clinical sites across the world. The studies will start over a period running from the fourth quarter of 2014 to the fourth quarter of 2015.
